Patent ID: 7476403

Claim:
A controlled release dosage form comprising: a. at least one drug which is clarithromycin, b. at least one polymer, having a viscosity less than 50 cps wherein the polymer having viscosity less than 50 cps is hydroxypropyl cellulose or hydroxypropyl methylcellulose wherein said polymer having a viscosity less than 50 cps is present in an amount more than 50% based on the weight of the dosage form, and c. at least one polymer, having a viscosity greater than 200 cps wherein the polymer having viscosity greater than 200 cps is hydroxypropyl cellulose or hydroxypropyl methylcellulose; said dosage form providing a therapeutic effect for at least 12 hours and wherein the maximum blood plasma concentration of the active drug (Cmax) when said dosage form is administered to a patient in a fed state is less than 50% higher or lower than the Cmax of said dosage form when administered in the fasted state, the area under the curve (AUC) when said dosage form is administered to a patient in a fed state in less than 20% higher or lower than the AUC of said dosage form when administered in the fasted state and the time to maximum blood plasma concentration (Tmax) when said dosage form is administered to a patient in a fed state is less than about 20% higher or lower than the Tmax of said dosage form when administered in the fasted state.